https://www.selleckchem.com/pr....oducts/2-bromohexade
The aim of this study was to evaluate the outcome of transcatheter mitral valve repair (TMVr) in patients with cardiogenic shock and significant mitral regurgitation (MR). Patients in cardiogenic shock with severe MR have a poor prognosis in the setting of conventional medical therapy. Because of its favorable safety profile, TMVr is being increasingly used as an acute therapy in this population, though its efficacy remains unknown. A multicenter, collaborative, patient-level analysis was conducted. Patients with cardio
Like
Comment
Share
